US FTC to check 10 web sites over bogus H1N1

27 May 2009

The Federal Trade Commission will revisit web sites whose operators have been warned that claims that their products can prevent, treat or cure  the influenza (A) H1N1 virus, commonly known as swine flu, that they  must be backed by scientific proof, or face law enforcement action.

"Scam artists follow the headlines, trying to make a fast buck with  products that play off the news and prey on concerned people," said  Eileen Harrington, acting director of the FTC's Bureau of Consumer  Protection. She added: "we're on-line and telling e-marketers their  sites must comply with the law." The FTC reminds consumers that the  only products recommended for use are the prescription antiviral drugs,  Tamiflu (oseltamivir) and Relenza (zanamivir).

The federal agency's staff identified 10 Web sites making suspect flu  treatment, prevention or cure claims. Of these, four USA-based web sites  already have complied, the FTC said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight